Anti-Infective Start-Ups See Opportunity In An Epidemiological Nightmare
This article was originally published in Start Up
Executive Summary
Infectious disease researchers have been warning for decades of the growing numbers of drug-resistant bacteria, and a certain subset of investors and companies sees this epidemiological nightmare as an alluring business opportunity. We profile three emerging anti-infective drug developers in this issue: Arsanis Biosciences, ContraFect, and Fedora Pharmaceuticals.